HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

VX-950 (Vertex/Mitsubishi).

Abstract
Vertex and Mitsubishi are developing VX-950 (LY-570310), the lead compound from a program of small-molecule inhibitors of the hepatitis C virus (HCV) NS3 protease, for the potential treatment of HCV infection. In November 2004, Vertex initiated a phase Ib European trial of VX-950 for the treatment of HCV infection.
AuthorsVincenzo Summa
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 6 Issue 8 Pg. 831-7 (Aug 2005) ISSN: 1472-4472 [Print] England
PMID16121690 (Publication Type: Journal Article, Review)
Chemical References
  • Antiviral Agents
  • NS3 protein, hepatitis C virus
  • Oligopeptides
  • Protease Inhibitors
  • Viral Nonstructural Proteins
  • telaprevir
Topics
  • Animals
  • Antiviral Agents (adverse effects, metabolism, pharmacokinetics, pharmacology, therapeutic use, toxicity)
  • Humans
  • Oligopeptides (adverse effects, metabolism, pharmacokinetics, pharmacology, therapeutic use, toxicity)
  • Patents as Topic
  • Protease Inhibitors (pharmacology, therapeutic use)
  • Structure-Activity Relationship
  • Viral Nonstructural Proteins (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: